ArticleBMC psychiatry2026
Identification of metabolism and inflammation-related biomarkers and potential drugs for schizophrenia based on comprehensive bioinformatics and machine learning.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSchizophrenia (SCZ) is a significant and widespread mental illness, where metabolism and inflammation-related genes (MIRGs) are crucial to understanding its underlying biology. This study aimed to identify peripheral biomarkers linked to metabolism and inflammation, validate these through the creation of a diagnostic model, investigate their connections with miRNA and transcription factors (TFs), and find potential drugs for targeting.
methodsThe datasets GES38484 and GSE54913 were obtained from the Gene Expression Omnibus (GEO) database, while the MIRGs were sourced from both the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and GeneCards. Key signature genes were identified using differential expression analysis, alongside techniques such as least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), Random Forest (RF), and extreme gradient boosting (XGBoost) methodologies. A logistic regression model was constructed for diagnostics, and its performance was assessed using a separate testing database. Furthermore, the signature genes were verified through RT-qPCR, and levels of immune infiltration were assessed using single-sample Gene Set Enrichment Analysis (ssGSEA). Finally, regulatory networks involving gene-miRNA and gene-TF interactions were created utilizing Cytoscape, while candidate drugs were identified through the Drug-Gene Interaction database.
resultsSix hub MIRGs were identified (HDC, NCKAP1L, FUCA1, CD40LG, CX3CR1, and SNAP25), leading to the development of a diagnostic signature based on these genes which served as potential biomarkers for SCZ (AUC = 0.884), further confirmed in the validation cohort (AUC = 0.933). The diagnostic model illustrated distinctions between low- and high-risk groups, highlighting differences in immune cell infiltration patterns. In-depth examination of these six genes indicated connections to 47 targeted miRNAs, 11 TFs within regulatory networks, and 40 potential therapeutic agents.
conclusionFindings from this research offer significant understanding regarding the function of MIRGs in SCZ, which could aid in the creation of viable candidate biomarkers and possible therapies that modify the disease for SCZ. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.